We explore what allosteric modulators are, their benefits and drawbacks, and which candidates are currently advancing through ...

Proceedings of the National Academy of Sciences of the United States of America, Vol. 119, No. 16 (April 19, 2022), pp. 1-10 (10 pages) Allosteric modulators of G-protein-coupled receptors (GPCRs) ...

Geneva, Switzerland, August 27, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators ...

Please provide your email address to receive an email when new articles are posted on . Change from baseline in gait variability did not differ between groups, regardless of cognitive load. Treatment ...

ADELAIDE, Australia, and CAMBRIDGE, Mass., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, ...

G-protein coupled receptor 68 (GPR68) is an acid-sensing protein receptor that has been implicated in inflammatory bowel disease (IBD) pathogenesis by its modulation of the inflammatory response and ...

Geneva, Switzerland, May 12, 2025-Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for ...

Neuphoria’s social anxiety disorder program will be discontinued based on the results from the AFFIRM-1 trial. Topline results were announced from a phase 3 trial evaluating BNC210 in patients with ...

NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ...